Table 4.
Laboratory features of patients infected with different EVs on admission in this study.
| EV types | All | CVA6 | CVA2 | CVA5 | CVA16 |
|---|---|---|---|---|---|
| No. of patients | N = 361 | N = 173 | N = 32 | N = 25 | N = 84 |
| WBC (109/L) | 12.9 (9.9–16.6) | 14.1 (10.4–17.7) | 13.1 (11.7–16.0) | 14.0 (12.2–16.4) | 11.0 (9.1–14.8) |
| Neutrophil (%) | 59.3 (46.7–70.3) | 57.9 (46.1–70.1) | 70.1 (50.2–77.0) | 73.6 (60.9–81.5)a | 55.0 (44.8–63.8) |
| Lymphocyte (%) | 29.4 (19.6–39.2) | 28.7 (20.5–41.0) | 21.7 (13.8–35.9) | 17.1 (11.8–26.8)b | 32.2 (25.7–41.1) |
| Platelet (109/L) | 314.0 (252.0–375.0) | 315.0 (256.0–383.0) | 292.0 (246.3–357.0) | 314.0 (243.0–345.0) | 318.5 (268.8–371.5) |
| No. of patients | N = 359 | N = 172 | N = 32 | N = 25 | N = 84 |
| AST (U/L) | 38.7 (33.1–44.9) | 39.2 (33.8–44.7) | 38.9 (36.2–48.4) | 39.1 (34.4–44.5) | 37.6 (31.6–45.0) |
| ALT (U/L) | 16.1 (13.1–20.2) | 16.0 (13.6–20.7) | 16.3 (13.6–19.9) | 16.3 (12.4–20.3) | 15.9 (12.6–18.7) |
| No. of patients | N = 212 | N = 102 | N = 20 | N = 9 | N = 52 |
| CRP (mg/L) | 19.8 (9.5–36.6) | 23.3 (12.0–42.0) | 23.2 (13.7–40.0) | 32.5 (27.7–58.2) | 9.9 (5.9–15.6)# |
| CRP (≥10 mg/L) | 105 (49.5%) | 53 (52.0%) | 16 (80.0%) | 8 (88.9%) | 26 (50.0%) |
| No. of patients | N = 276 | N = 137 | N = 22 | N = 19 | N = 59 |
| GLU (mmol/L) | 5.0 (4.3–5.5) | 5.0 (4.4–5.4) | 4.6 (4.0–5.8) | 5.5 (4.7–5.9) | 4.9 (3.8–5.6) |
| GLU (≥6.1 mmol/L) | 38 (13.8%) | 15 (10.9%) | 4 (18.2%) | 3 (15.8%) | 9 (15.3%) |
a
CVA5 vs. CVA6 and CVA16, P were < 0.05;
b
CVA5 vs. CVA6 and CVA16, P were < 0.05.
#
Compared with CVA6, CVA2, and CVA5 groups, P were < 0.05.
AST, aspartate aminotransferase; ALT, alanine aminotransferase; CRP, C-reactive protein; GLU denotes glucose.